Current Report Filing (8-k)
January 11 2023 - 04:02PM
Edgar (US Regulatory)
false00-00000000001534248NASDAQNASDAQ00015342482023-01-112023-01-110001534248cmmb:AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember2023-01-112023-01-110001534248cmmb:OrdinarySharesNoParValuePerShareMember2023-01-112023-01-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11,
2023
Chemomab Therapeutics Ltd.
(Exact name of Registrant as Specified in Its Charter)
|
State of Israel |
001-38807
|
81-3676773
|
|
(State or Other Jurisdiction |
(Commission |
(IRS Employer |
|
of Incorporation) |
File Number) |
Identification No.) |
Kiryat Atidim, Building
7
|
|
|
Tel Aviv, Israel |
6158002
|
|
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code:
+972-77-331-0156
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
|
|
☐
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
|
☐
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each class |
|
Trading
Symbol(s) |
|
Name of each
exchange
on which registered |
American Depositary Shares, each representing twenty (20) ordinary
shares, no par value per share
|
|
CMMB
|
|
Nasdaq
Capital Market
|
|
|
|
|
|
|
Ordinary shares, no par value per share
|
|
N/A |
|
Nasdaq
Capital Market* |
* Not
for trading; only in connection with the registration of American
Depositary Shares.
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this
chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report on Form 8-K, and
incorporated into this Item 7.01 by reference, is an updated
corporate presentation of the Company.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit
Number
|
Exhibit Description
|
|
|
|
|
Exhibit 104
|
Cover Page Interactive Data File - the cover page XBRL tags are
embedded within the Inline XBRL document.
|
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
CHEMOMAB THERAPEUTICS LTD.
|
|
|
|
|
|
|
|
Date: January 11, 2023
|
By:
|
/s/ Donald Marvin
|
|
|
|
|
Name: Donald Marvin
|
|
|
|
|
Title: Executive Vice President, Chief Financial Officer and Chief
Operating Officer
|
|
Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
From Feb 2023 to Mar 2023
Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
From Mar 2022 to Mar 2023
